U.S. District Court Issues Favorable Decision for IQVIA Against Veeva
IQVIA (NYSE:IQV), a global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today announced that the U.S. District Court of New Jersey issued a favorable decision in its litigation with Veeva Systems, Inc. (NYSE:VEEV). The Court ruled on IQVIA's motion for sanctions, finding Veeva engaged in massive destruction of evidence, engaged in a cover-up of its wrong-doing, and repeatedly lied about its actions. The court sanctioned Veeva five separate times in the decision to punish Veeva for its violations of rules in the litigation, including multiple adverse jury instructions, limitations on the use of evidence at trial and an award of legal fees and costs. Specific language from the decision includes:
Engaging Fraud & Destruction of Evidence
Veeva Misappropriation of IQVIA Intellectual Property
Theft & Intentional Covr-Up
"We are pleased with the Court's decision, which exposes Veeva's longstanding deceptive business practices, as well as its pattern of corporate theft," said Harvey Ashman, senior vice president, deputy general counsel, IQVIA. "Veeva stole IQVIA intellectual property from client files, they knew it was wrong, they destroyed evidence to cover-up their wrongdoing, and then they lied about it. Veeva lied to IQVIA, the court, their clients, the media, and investors. Veeva's disregard for intellectual property rights, contractual obligations, and the truth is clear. IQVIA looks forward to successfully resolving our ongoing litigation for the benefit of our clients and reaffirming protections for intellectual property, innovation, and investment."
IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources and extensive domain expertise. IQVIA Connected Intelligence™ delivers powerful insights with speed and agility - enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 72,000 employees, IQVIA conducts operations in more than 100 countries.
IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA's insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors, and scientific advances, to advance their path toward cures. To learn more, visit www.iqvia.com.
The Office Phone Reinvented (Again): Making Money with VoIP
$15,000 GRAND PRIZE GIVEAWAY DRAWING - Must Be Present to Win